In the last trading session, 3.22 million Roivant Sciences Ltd (NASDAQ:ROIV) shares changed hands as the company’s beta touched 1.27. With the company’s per share price at $8.80 changed hands at -$0.17 or -1.90% during last session, the market valuation stood at $7.07B. ROIV’s last price was a discount, traded about -50.45% off its 52-week high of $13.24. The share price had its 52-week low at $4.71, which suggests the last value was 46.48% up since then. When we look at Roivant Sciences Ltd’s average trading volume, we note the 10-day average is 4.93 million shares, with the 3-month average coming to 6.39 million.
Analysts gave the Roivant Sciences Ltd (ROIV) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ROIV as a Hold, 9 felt it is a Buy and 0 rated the stock as Underweight. Roivant Sciences Ltd’s EPS for the current quarter is expected to be -$0.33.
Roivant Sciences Ltd (NASDAQ:ROIV) trade information
Instantly ROIV was in red as seen at the end of in last trading. With action -2.76%, the performance over the past five days has been red. The drop to weekly highs of 9.60 on Monday, 11/20/23 subtracted -1.90% to the stock’s daily price. The company’s shares are showing year-to-date upside of 10.14%, with the 5-day performance at -2.76% in the red. However, in the 30-day time frame, Roivant Sciences Ltd (NASDAQ:ROIV) is -8.90% down. Looking at the short shares, we see there were 33.23 million shares sold at short interest cover period of 4.18 days.
The consensus price target for the stock as assigned by Wall Street analysts is $15.88, meaning bulls need an upside of 44.58% from its current market value. According to analyst projections, ROIV’s forecast low is $11.00 with $23.00 as the target high. To hit the forecast high, the stock’s price needs a -161.36% plunge from its current level, while the stock would need to soar -25.0% for it to hit the projected low.
Roivant Sciences Ltd (ROIV) estimates and forecasts
Data shows that the Roivant Sciences Ltd share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -8.90% over the past 6 months, a 31.01% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Roivant Sciences Ltd will rise 32.70%, while the growth in revenue is estimated to hit -60.00% for the next quarter. Year-over-year growth is forecast to reach 110.60% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of $31.15 million. 8 analysts are of the opinion that Roivant Sciences Ltd’s revenue for the quarter ending Mar 2024 will be $35.5 million. The estimates for the next quarter sales put growth at 29.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.79%. The 2023 estimates are for Roivant Sciences Ltd earnings to decrease by -11.11%.
Roivant Sciences Ltd is expected to release its next quarterly earnings report between February 12 and February 16.